Biotechnology

Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All

TAIPEI, July 12, 2023 /PRNewswire/ -- As cell therapies continue to rank among the most expensive of cancer treatments,BeiGene is quietly charting a different path that would enable more equitable access for all.

2023-07-12 06:00 2404

DISCOVERY LIFE SCIENCES ACCELERATES CLINICAL TRIALS WITH ADDITION OF FULL-SPECTRUM CLINICAL FLOW CYTOMETRY

Integrates state-of-the-art flow cytometry clinical trial services with leading genomics, proteomics, and molecular pathology solutions under one roof HUNTSVILLE, Ala., July 11, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the laun...

2023-07-11 20:05 2916

Doer Biologics Announces License Agreement with BioNTech

HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE (Nasdaq...

2023-07-11 11:49 1939

Race executes global license agreement with City of Hope to access FTO IP

* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...

2023-07-11 07:30 2412

Quest PharmaTech Provides Product Development Update

EDMONTON, AB, July 11, 2023 /PRNewswire/ -- Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies announced that a U.S patent has been granted...

2023-07-11 04:30 2106

TCI Introduces VeCollal®, the Biomimetic Collagen Most Identical to Human Collagen from Belgium Validated by Human Clinical Study.

TAIPEI, July 10, 2023 /PRNewswire/ -- VeCollal®, located in Belgium, is a renowned global leader in developing collagen sourced from non-animal origins. The company possesses a strong scientific background and comprehensive clinical trial data. Dr. Josué Vázquez, the Chief Scientist of VeCollal®,...

2023-07-10 20:21 2998

Race executes global license agreement with City of Hope to access FTO IP

* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...

2023-07-10 19:30 1835

Patsnap: Supercharging FTO Search with Degenerate Sequence Searching

LONDON, July 10, 2023 /PRNewswire/ -- Patsnap's biological sequence database (Bio) statistics show that the occurrence of such special sequences in global patent literature is not insignificant. There are approximately 7.4 million nucleotide sequences, ac...

2023-07-10 18:24 1899

BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM

HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Broncus Holding Corporation (HKG:2216) has completed the first case of registered clinical trials of its targeted lung denervation (''TLD'') radiofrequency ablation system. The multi-center clinical randomized controlled trial on the ''treatment of C...

2023-07-10 12:56 2488

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fu...

2023-07-10 10:24 2335

280 Bio receives IND approval from the FDA for YL-17231

---The Company announces to initiate Phase 1 Clinical Trial with the KRAS inhibitor YL-17231 in US-- SHANGHAI and SOUTH SAN FRANCISCO, Calif. , July 7, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today annou...

2023-07-07 20:00 2827

Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years

SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized onJune 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years. This prestigious sub-lis...

2023-07-07 19:43 4685

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received ...

2023-07-07 15:52 2899

Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs

SUZHOU, China, July 6, 2023 /PRNewswire/ -- GeneQuantum Healthcare, a leader in the innovative bioconjugation technologies for ADC new drug development, announced the expansion of its partnership with a South Korean biotech company Aimed Bio today. This strategic collaboration aims to jointly dev...

2023-07-07 10:19 1937

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment

SHANGHAI, July 6, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the completion of patient enrollment for...

2023-07-06 18:33 2007

Genesis MedTech Receives Approval for Launch in China for ArtiSential™

SINGAPORE, July 6, 2023 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced that its ArtiSential™, a revolutionary series of articulating laparoscopic instruments, has successfully obtained approval from theChina's National Medical Products Administration (NMPA) for...

2023-07-06 18:00 2051

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China

SUZHOU, China and ROCKVILLE, Md., July 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of the Chi...

2023-07-06 10:38 1813

MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea

SEOUL, South Korea, July 6, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced its ultra-high-throughput genetic sequencer DNBSEQ-T7 received the medical device registration certificate from the Korea Ministry of...

2023-07-06 09:00 2814

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...

2023-07-06 07:25 3050

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...

2023-07-06 07:19 3029
1 ... 93949596979899 ... 307

Week's Top Stories